Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chiniofon is an iodinated quinoline derivative that serves as a luminal amebicide and topical antiseptic. Historically used for the treatment of intestinal amebiasis caused by *Entamoeba histolytica*, it is typically formulated as a mixture of 7-iodo-8-hydroxyquinoline-5-sulfonic acid and sodium bicarbonate. Beyond its anti-protozoal activity, chiniofon exhibits bacteriostatic properties and has been investigated for use in wound care, particularly for chronic venous ulcers and radiation damage. Studies have indicated that chiniofon does not inhibit fibroblast growth, a common side effect of other antiseptics like PVP-iodine, and may possess anti-inflammatory activity. Its systemic use has largely been superseded by more modern amebicides such as metronidazole.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chiniofon.